Loring Wolcott & Coolidge Fiduciary Advisors LLP Sarepta Therapeutics, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q3 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 26 shares of SRPT stock, worth $3,063. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26Holding current value
$3,063% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
548Shares Held
85.8MCall Options Held
3.64MPut Options Held
1.68M-
Black Rock Inc. New York, NY10.3MShares$1.22 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.06 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$509 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$488 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$450 Million0.33% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $10.3B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...